Methods and compositions are disclosed for treating disorders of the contact activation system, comprising the administration of at least one C1-Inhibitor (C1-INH) and at least one Factor XII (FXII) inhibitor.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/616 - Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Provision of educational services relating to health; Publication of the results of clinical trials; Education services relating to therapeutic treatments. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing information about the results of clinical trials for pharmaceutical products; Providing scientific information in the field of medical disorders and their treatment. Provision of pharmaceutical information; Provision of medical information.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of blood conditions, diseases, disorders, and treatment; promoting the interests of patients with blood disorders by means of public advocacy, including through social media and events organized by others; promoting public awareness of the need for influenza immunization and vaccination programs; public policy research services concerning policy initiatives for blood conditions and blood related diseases, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals; promoting the donation of blood and plasma by means of arranging and conducting incentive reward programs Providing medical information concerning blood products for humans, especially blood proteins for therapeutic use, blood clotting agents and antihemophilic factors, fibrinogen concentrate, and pharmaceutical preparations for the treatment of blood or bleeding disorders and deficiencies of blood coagulation; providing medical information and treatment information in the field of health; medical services, namely, providing medical information concerning blood products, providing medical information concerning health products and services; health care, namely, providing health care information in person, via the internet, and through the distribution of printed matter
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals, medical and veterinary preparations and substances; biological and biotechnological preparations for medical use; blood plasma; blood products in this class; products derived from blood and products derived from recombinant DNA technology; vaccines; serums; antibodies; monoclonal antibodies; reagent red blood cells; test kits in this class; chemical preparations for testing blood for medical purposes; diagnostic preparations and materials, for medical and veterinary purposes; medical dressings, coverings and applicators. Computer software; application software; downloadable software applications; software as a medical device [SaMD], downloadable; computer software and programs; electronic or recorded multimedia publications; publications sold in an electronic format and publications provided or distributed on line; electronic audio visual teaching materials; printed publications in electronically readable or downloadable form; electronic publications provided on line, from the internet or from any other communication network; educational materials in the form of computer software and programs, including applications for use on mobile devices; educational materials in the form of pre-recorded media including discs, dvds, compact discs, flash drives; all aforementioned goods in the fields of pharmacy, medicine and/or medical technology. Surgical and medical apparatus and instruments; implantable medical devices; analysis apparatus and instruments in this class; test kits in this class. Printed matter and publications; instructional and teaching material; journals, brochures, pamphlets, flyers, posters; all aforementioned goods in the fields of pharmacy, medicine and/or medical technology. Advertising, marketing and promotion services in the fields of pharmacy, medicine and/or medical technology; advertising services to promote public awareness of medical conditions; automated processing of medical data; compilation of statistical data relating to medical research; computerized management of medical records and file; medical cost management; medical transcription services; administrative services for medical referrals; business management services in this class related to the manufacture, marketing and distribution of pharmaceutical products and medical products and supplies and medical technological products; retail and wholesale services including retail and wholesale services for pharmaceutical products and medical products and supplies, veterinary and sanitary preparations and medical supplies and medical technological products. Treatment of waste materials in the fields of pharmacy, medicine and/or medical technology; recycling of medical waste; treatment of biological products including custom manufacturing and fractionation of blood; production of reagents and ancillary products for immunohaematology laboratories; processing of human blood plasma, namely, removing whole blood and separating red blood cells from plasma; treatment of human blood and plasma; fractionation of human blood and plasma; manufacturing of human blood and plasma; custom manufacture of medical devices for others. Education services including medical education services; health education; consultancy services relating to education; provision of education services via an online forum; provision of training and education courses; publication of educational materials; dissemination of educational material; weblog (blog) services; electronic publication of information on a wide range of topics, including online and over a global computer network; all aforementioned services in the fields of pharmacy, medicine and/or medical technology; organisation of conferences and symposia in the field of medical science; publication of medical publications publishing and issuing scientific papers in relation to medical technology. Scientific and technological services in the fields of pharmacy, medicine and/or medical technology; research and development services in the fields of pharmacy, medicine and/or medical technology, including scientific, medical, pharmaceutical and blood products research and development services; clinical trials; conducting clinical trials; provision of testing facilities in the fields of pharmacy, medicine and/or medical technology; rental of research facilities in the fields of pharmacy, medicine and/or medical technology; laboratory analysis and research in the fields of pharmacy and medicine; management of scientific research projects in the fields of pharmacy, medicine and/or medical technology; preparation of technical studies, technical reports, scientific reports in the fields of pharmacy, medicine and/or medical technology; preparation of scientific research projects in the fields of pharmacy, medicine and/or medical technology; preparation of statistics or reports relating to scientific research in the fields of pharmacy, medicine and/or medical technology; preparation of statistics or reports relating to medical research; preparation of medical research projects; provision of research services and facilities, provision of research results, information and outcomes in the fields of pharmacy, medicine and/or medical technology; provision of information relating to the aforementioned services; advisory and consultancy services relating to the aforementioned services; dissemination of information relating to the aforementioned services over a global computer network; medical laboratory services, namely, scientific testing and screening services, namely, testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma; medical analysis services relating to the treatment of patients; medical consultancy services. Medical services; medical information services; health care services; health care information services; medical diagnostic services; patient support services; medical, pharmaceutical and blood products advice and consultancy services; medical advisory services; information services concerning pharmaceuticals, medical products and blood products; dissemination of information regarding the aforementioned services over a global computer network; blood bank services; operating blood and plasma collection centres; medical testing and screening services; medical testing of human blood plasma; collection, processing and testing of human blood and plasma.
The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary
Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and
Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary
Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and
Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary
Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and
Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,
fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma
fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and
prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations
for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of
hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;
blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary
medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits
consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell
cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for
medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for
the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,
namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody
for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,
antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; antibodies; blood products
(term considered too vague by the International Bureau -
rule 13 (2) (b) of the Regulations); blood plasma; blood
plasma fractions; blood plasma products for medical
purposes; recombinant proteins for medical purposes; cell
cultures for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; antibodies; blood products
(term considered too vague by the International Bureau -
rule 13 (2) (b) of the Regulations); blood plasma; blood
plasma fractions; blood plasma products for medical
purposes; recombinant proteins for medical purposes; cell
cultures for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; antibodies; blood products;
blood plasma; blood plasma fractions; blood plasma products
for medical purposes; recombinant proteins for medical
purposes; cell cultures for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); pharmaceutical antibodies for the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibodies for use as an anti-infective and as an anti-inflammatory; pharmaceutical antibodies for the treatment of hereditary angioedema (HAE); blood products, namely, blood substitutes, blood for medical purposes, cord blood for medical purposes, blood platelets for medical purposes; blood plasma; blood plasma fractions; blood plasma products for medical purposes, namely, albumin, anti-inhibitor coagulants, immune globulins, thrombin generators, antihemophilics, fibrinogen generators; recombinant DNA gene proteins for medical purposes; cell cultures for medical laboratory use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of pneumonia; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for the treatment of influenza; pharmaceutical preparations for the treatment of Hereditary Angioedema (HAE); pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis(IPF) and Interstitial Lung Diseases (ILD); monoclonal antibodies for medical purposes; blood products namely pharmaceutical preparations for the treatment of hemophilia, drug preparations to aid in blood clotting; blood plasma; blood plasma fractions; blood plasma for medical purposes; recombinant proteins arrays for medical diagnosis purposes; cell cultures for medical purposes, namely, stem cells for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD); pharmaceutical antibodies for the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibodies for use as an anti-infective and as an anti-inflammatory; pharmaceutical antibodies for the treatment of hereditary angioedema (HAE); blood products, namely, blood substitutes, blood for medical purposes, cord blood for medical purposes, blood platelets for medical purposes; blood plasma; blood plasma fractions; blood plasma products for medical purposes, namely, albumin, anti-inhibitor coagulants, immune globulins, thrombin generators, antihemophilics, fibrinogen generators; recombinant DNA gene proteins for medical purposes; cell cultures for medical laboratory use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; and not for smoking cessation treatment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
